Skip to main content
Top
Published in:

03-01-2024 | Pancreatic Cancer | ASO Research Letter

Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer

Authors: Austin M. Eckhoff, MD, Elishama Kanu, MD, Ashley Fletcher, BS, Matthew Bao, BS, Vasily N. Aushev, PhD, Erik Spickard, PhD, Daniel P. Nussbaum, MD, Peter J. Allen, MD

Published in: Annals of Surgical Oncology | Issue 3/2024

Login to get access

Abstract

Background

Pancreatic adenocarcinoma (PDAC) is highly lethal with up to 80% of resected patients experiencing disease recurrence within 2 years (Watanabe, Nakamura, Kimura et al in Int J Mol Sci 23(19):11521, 2022). Cross-sectional imaging and serum tumor markers are used for monitoring post-operative recurrence; however, both have significant limitations (Edland, Tjensvoll, Oltedal et al in Mol Oncol 17:1857–1870, 2023). Circulating tumor DNA (ctDNA) has emerged as a valuable prognostic tool to measure molecular residual disease (MRD) and predict recurrence in solid tumors (Watanabe, Nakamura, Kimura et al in Int J Mol Sci 23(19):11521, 2022). In this study, we evaluated the feasibility of a personalized, tumor-informed ctDNA assay to detect recurrence prior to standard surveillance tools in patients with PDAC.

Patients and Methods

After Institutional Review Board (IRB) approval (Pro00106870), we assessed serial ctDNA measurements (n = 177) from 35 patients with resectable PDAC treated by either upfront resection or neoadjuvant chemotherapy. Plasma samples (median 4 ml, interquartile range 0.6–5.9 ml) were isolated from blood collected in EDTA tubes and banked at diagnosis, during neoadjuvant therapy if applicable, on the day of surgery, and every 2–3 months postoperatively. A tumor-informed assay (Signatera™, Natera, Inc.) that tracks up to 16 individual-specific, somatic single nucleotide variants in the corresponding patient’s plasma samples were used for ctDNA detection. Survival was calculated using Kaplan–Meier curves, and significance was determined with the log-rank test.

Results

Personalized ctDNA assays were successfully designed for all patients (with 32/35 patients having 16-plex assays). Median follow-up from initial treatment was 13 months (range 1–26 months; Table 1). ctDNA-positivity at any time point was observed in 40% (14/35) of patients. During the follow-up period, 18 patients (51%) developed radiographic evidence of recurrence after a median of 9 months of follow-up (range 1–26 months). At the time of radiographic recurrence, 50% (9/18) of patients were ctDNA-positive. During the immediate postoperative period (up to 9 weeks post-surgery), RFS and OS were significantly inferior in patients who were ctDNA-positive versus ctDNA-negative (RFS 97 versus 297 days, p < 0.001; OS 110 versus 381 days, p < 0.001; Fig. 1).
Table 1
Cohort demographics (N = 35); patient demographics, tumor characteristics, and survival
Gender (%)
Female 17 (49%)
Male 18 (51%)
Median age (IQR)
70 years (65–75 years)
Neoadjuvant treatment (%)
11 (31%)
Median sample plasma volume (IQR)
4.0 mL (0.6–5.9 mL)
Median follow-up (range)
13 months (1–26 months)
Median initial CA 19-9 in U/mL (IQR)
56 (18–160)
Median tumor size in cm (IQR)
2.5 (1.8–3.3)
Median number of positive lymph nodes (IQR)
1 (0–3)
Median recurrence-free survival
9.4 months
Median overall survival
N/A (not reached)

Discussion

Our study demonstrates the feasibility of tumor-informed ctDNA-based MRD testing in resectable PDAC and shows that MRD detected by ctDNA within the immediate postoperative period portends a dismal prognosis. This information is valuable for both patients and clinicians in setting prognostic expectations.
Literature
Metadata
Title
Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer
Authors
Austin M. Eckhoff, MD
Elishama Kanu, MD
Ashley Fletcher, BS
Matthew Bao, BS
Vasily N. Aushev, PhD
Erik Spickard, PhD
Daniel P. Nussbaum, MD
Peter J. Allen, MD
Publication date
03-01-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14751-2
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now